Tischer Alexander, Machha Venkata R, Frontroth Juan P, Brehm Maria A, Obser Tobias, Schneppenheim Reinhard, Mayne Leland, Walter Englander S, Auton Matthew
Division of Hematology, Departments of Internal Medicine and Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA.
Laboratorio de Hemostasia y Trombosis, Servicio de Hematologia y Oncologia, Hospital de Pediatria, "Prof. Dr. Juan P. Garrahan", Buenos Aires, Argentina.
J Mol Biol. 2017 Jul 7;429(14):2161-2177. doi: 10.1016/j.jmb.2017.05.013. Epub 2017 May 19.
Mutation of the cysteines forming the disulfide loop of the platelet GPIbα adhesive A1 domain of von Willebrand factor (VWF) causes quantitative VWF deficiencies in the blood and von Willebrand disease. We report two cases of transient severe thrombocytopenia induced by DDAVP treatment. Cys1272Trp and Cys1458Tyr mutations identified by genetic sequencing implicate an abnormal gain-of-function phenotype, evidenced by thrombocytopenia, which quickly relapses back to normal platelet counts and deficient plasma VWF. Using surface plasmon resonance, analytical rheology, and hydrogen-deuterium exchange mass spectrometry (HXMS), we decipher mechanisms of A1-GPIbα-mediated platelet adhesion and resolve dynamic secondary structure elements that regulate the binding pathway. Constrained by the disulfide, conformational selection between weak and tight binding states of A1 takes precedence and drives normal platelet adhesion to VWF. Less restrained through mutation, loss of the disulfide preferentially diverts binding through an induced-fit disease pathway enabling high-affinity GPIbα binding and firm platelet adhesion to a partially disordered A1 domain. HXMS reveals a dynamic asymmetry of flexible and ordered regions common to both variants, indicating that the partially disordered A1 lacking the disulfide retains native-like structural dynamics. Both binding mechanisms share common structural and thermodynamic properties, but the enhanced local disorder in the disease state perpetuates high-affinity platelet agglutination, characteristic of type 2B VWD, upon DDAVP-stimulated secretion of VWF leading to transient thrombocytopenia and a subsequent deficiency of plasma VWF, characteristic of type 2A VWD.
血管性血友病因子(VWF)血小板糖蛋白Ibα粘附A1结构域中二硫键环形成的半胱氨酸突变会导致血液中VWF定量缺乏以及血管性血友病。我们报告了两例因去氨加压素治疗引起的短暂性严重血小板减少症病例。通过基因测序鉴定出的Cys1272Trp和Cys1458Tyr突变暗示了一种异常的功能获得表型,表现为血小板减少,随后血小板计数迅速恢复正常且血浆VWF缺乏。我们使用表面等离子体共振、分析流变学和氢-氘交换质谱(HXMS)来解读A1-GPIbα介导的血小板粘附机制,并解析调节结合途径的动态二级结构元件。受二硫键限制,A1在弱结合状态和紧密结合状态之间的构象选择占主导地位,并驱动正常血小板与VWF粘附。通过突变,二硫键限制减少,优先通过诱导契合疾病途径改变结合,从而实现高亲和力GPIbα结合以及血小板与部分无序的A1结构域的牢固粘附。HXMS揭示了两种变体共有的柔性和有序区域的动态不对称性,表明缺乏二硫键的部分无序A1保留了类似天然的结构动力学。两种结合机制具有共同的结构和热力学特性,但在疾病状态下增强的局部无序会在去氨加压素刺激VWF分泌导致短暂性血小板减少以及随后血浆VWF缺乏(2A型血管性血友病的特征)时,持续维持2B型血管性血友病特有的高亲和力血小板凝集。